Thrombosis and cancer: Trousseau syndrome revisited

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 1, 2009, Pages 3-8

  Donati, Maria Benedetta ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

cancer procoagulant; experimental metastases; heparin; malignant cells; thrombosis; tissue factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; BIOLOGICAL MARKER; CYSTEINE PROTEINASE; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RETINOIC ACID; WARFARIN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; CELL ADHESION; CELL INTERACTION; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME ACTIVITY; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCOAGULABILITY; IDIOPATHIC DISEASE; METASTASIS; NEOPLASM; NONHUMAN; OCCULT CANCER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION; TROUSSEAU SYNDROME; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTICOAGULANTS; HUMANS; NEOPLASMS; SYNDROME; THROMBOSIS;

EID: 61649128786     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.01.005     Document Type: Review

References (55)

1. Trousseau A. Phlegmasia Alba Dolens. Clinique Médicale de l'Hçtel Dieu de Paris. 2nd edn vol 3 (1865), JB Baillère, Paris p. 659-12
2. Billroth T. Lectures on surgical pathology and therapeutics:a handbook for students and practitioners. 8th edn (1878), The New Sydenham Society, London p. 1877-78
3. Cliffton E.E., and Grossi C.E. Fibrinolytic activity of human tumors as measured by the fibrin-plate method. Cancer 8 (1955) 1146-1154
4. Grossi C.E., Agostino D., and Cliffton E.E. The effect of human fibrinolysin on pulmonary metastases of Walker 256 carcinoma. Cancer Res 20 (1960) 605-608
5. Agostino D., Grossi C.E., and Cliffton E.E. Effect of heparin on circulating Walker carcinosarcoma 256 cells. J Natl Cancer Inst 5 (1961) 463-473
6. Cliffton E.E., and Agostino D. Factors affecting the development of metastatic cancer. Effect of alterations in clotting mechanism. Cancer 15 (1962) 276-283
7. Donati M.B. Thrombosis and cancer; a personal view. Thromb Haemost 98 (2007) 126-128
8. Dolfini E., Azzarone B., Pedulla D., et al. Characterization of human fibroblasts from cancer patients: loss of fibrin clot retractile activity after 'in vitro' spontaneous transformation. Eur J Cancer 12 (1976) 823-825
9. Donati M.B., Dolfini E., Morasca L., et al. Fibrin clot retraction by a rat rhabdomyosarcoma cell line. Thromb Res 8 (1976) 707-711
10. Curatolo L., Colucci M., Cambini A.L., et al. Evidence that cells from experimental tumours can activate coagulation factor X. Br J Cancer 40 (1979) 228-233
11. Poggi A., Polentarutti N., Donati M.B., et al. Blood coagulation changes in mice bearing Lewis lung carcinoma, a metastasizing tumor. Cancer Res 37 (1977) 272-277
12. Chmielewska J., Poggi A., Mussoni L., et al. Blood coagulation changes in JW sarcoma, a new metastasizing tumour in mice. Eur J Cancer 16 (1980) 1399-1407
13. Mussoni L., Poggi A., de Gaetano G., et al. Effect of ditazole, an inhibitor of platelet aggregation, on a metastasizing tumour in mice. Br J Cancer 37 (1978) 126-129
14. Poggi A., Mussoni L., Kornblihtt L., et al. Warfarin enantiomers, anticoagulation, and experimental tumor metastasis. Lancet 1 (1978) 163-164
15. Chmielewska J., Poggi A., Janik P., et al. Effect of defibrination with batroxobin on growth and metastasis of JW sarcoma in mice. Eur J Cancer 16 (1980) 919-923
16. Gordon S.G., Franks J.J., and Lewis B. Cancer procoagulant A: a factor X-activating procoagulant from malignant tissue. Thromb Res 6 (1975) 127-137
17. Colucci M., Delaini F., De Bellis Vitti G., et al. Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency. Biochem Pharmacol 32 (1983) 1689-1691
18. Lorenzet R., Bottazzi B., Locati D., et al. Failure of warfarin to affect the tissue factor activity and the metastatic potential of murine fibrosarcoma cells. Eur J Cancer Clin Oncol 21 (1985) 263-265
19. Donati M.B., Gambacorti P., Casali B., et al. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res 46 (1986) 6471-6474
20. Grignani G., Falanga A., Pacchiarini L., et al. Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties. Int J Cancer 42 (1988) 554-557
21. Falanga A., Alessio M.G., Donati M.B., et al. A new procoagulant in acute leukemia. Blood 71 (1988) 870-875
22. Donati M.B., Falanga A., Consonni R., et al. Cancer procoagulant in acute non lymphoid leukemia: relationship of enzyme detection to disease activity. Thromb Haemost 64 (1990) 11-16
23. Falanga A., Iacoviello L., Evangelista V., et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 86 (1995) 1072-1081
24. Falanga A., and Gordon S.G. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 24 (1985) 5558-5567
25. Barbui T., Finazzi G., and Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukaemia. Blood 91 (1998) 3093-3102
26. Roncaglioni M.C., D'Alessandro A.P., Casali B., et al. Gamma-glutamyl carboxylase activity in experimental tumor tissues: a biochemical basis for vitamin K dependence of cancer procoagulant. Haemostasis 16 (1986) 295-299
27. Lorenzet R., Peri G., Locati D., et al. Generation of procoagulant activity by mononuclear phagocytes: a possible mechanism contributing to blood clotting activation within malignant tissues. Blood 62 (1983) 271-273
28. Rambaldi A., Alessio G., Casali B., et al. Induction of monocyte-macrophage procoagulant activity by transformed cell lines. J Immunol 136 (1986) 3848-3855
29. Mantovani A., Allavena P., Sica A., et al. Cancer-related inflammation. Nature 454 (2008) 436-444
30. Falanga A., Brenner B., and Rickles F. Fourth Intern.Conf. on Thromb.and Hemost. Issues in Cancer, Bergamo, Italy. Thromb Res 120 Suppl. 2 (2007)
31. Levine M.N., Gent M., Hirsh J., et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318 (1988) 404-407
32. Levine M., Hirsh J., Gent M., et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343 (1994) 886-889
33. Barbui T., and Falanga A. Thalidomide and thrombosis in multiple myeloma. J Thromb Haemost 3 (2003) 421-422
34. Prandoni P., Lensing A.W., Buller H.R., et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327 (1992) 1128-1133
35. Prandoni P., Falanga A., and Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 6 (2005) 401-410
36. Carrier M., LeGal G., Wells P.S., et al. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?. Ann Int Med 149 (2008) 323-333
37. Zacharski L.R., and Donati M.B. Registry of clinical trials of antithrombotic drugs in cancer. The Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Subcommittee on Hemostasis and Malignancy. Thromb Haemost 61 (1989) 526-528
38. Zacharski L.R., Donati M.B., and Rickles F.R. Registry of clinical trials of antithrombotic drugs in cancer: Second report. Thromb Haemost 70 (1993) 357-360
39. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction:ISIS-2.ISIS-2 (Second International Study of Infarct Survival). Collaborative Group. Lancet 2 (1988) 349-360
40. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardio. Lancet 336 (1990) 65-71
41. Donati M.B., and Poggi A. Malignancy and haemostasis. Br J Haematol 44 (1980) 173-182
42. Poggi A., Donati M.B., and Garattini S. Fibrin and cancer cell growth: problems in the evaluation of experimental models. Malignancy and the hemostatic system (1981), Raven Press, New York 89-101
43. Bani M.R., Falanga A., Alessio M.G., et al. Blood coagulation changes in nude mice bearing human colon carcinomas. Int J Cancer 50 (1992) 75-79
44. Falanga A. The effect of anticoagulant drugs on cancer. J Thromb Haemost 2 (2004) 1263-1265
45. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular- weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
46. Altinbas M., Coskun H.S., Er O., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2 (2004) 1266-1271
47. Kakkar A.K., Levine M.N., Kadziola Z., et al. Low molecular weight heparin therapy with dalteparin and survival in advanced cancer: the framing advanced malignancy outcome study (FAMOUS). J Clin Oncol 22 (2004) 1944-1948
48. Klerk C.P., Smorenburg S.M., Otten H.M., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23 (2005) 2130-2135
49. Lee A.Y., Rickles F.R., Julian J.A., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23 (2005) 2123-2129
50. Maugeri N., de Gaetano G., Barbanti M., et al. Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparins. Haematologica 90 (2005) 815-821
51. Maugeri N., Di Fabio G., Barbanti M., et al. Parnaparin, a low molecular weight heparin, prevents P-selectin- dependent formation of platelet- leukocyte aggregates in human whole blood. Thromb Haemost 97 (2007) 965-973
52. Lorenzet R., and Donati M.B. Blood clotting activation, angiogenesis and tumor metastasis: any role for TFPI?. Thromb Haemost 87 (2002) 928-929
53. Donati M.B., and Lorenzet R. Coagulation factors and tumor cell biology: the role of tissue factor. Pathophysiol Haemost Thromb 33 Suppl. 1 (2003) 22-25
54. Donati M.B., Falanga A., and Lorenzet R. Cancer and thrombosis: a two way interaction. Thrombosis. Fundamental and clinical aspects (2003), Leuven University Press 417-431
55. Napoleone E., Zurlo F., Latella M.C., et al. Paclitaxel downregulates tissue factor in cancer and host tumour-associated cells. Eur J Cancer (2008 Nov 27) [Epub ahead of print]